Protego Biopharma key facts
as of Oct 2026- Developer of a small molecule therapeutics platform designed to reprogram protein folding for the treatment of various systemic amyloid diseases and protein misfolding diseases.
- Protego Biopharma is valued at approximately $216.5M as of Oct 2026 (last reported valuation).
- It has raised $182.1M across 3 recorded rounds; the latest was Early Stage VC ($32.9M) in Oct 2025.
- Notable investors include Lightspeed Venture Partners, Johnson & Johnson Innovation - JLABS, Digitalis Ventures, Forbion, Novartis Venture Fund — 12 tracked in total.
- Protego Biopharma has filed 3 Form Ds with the SEC since 2019, most recently Dec 2025 ($32.9M sold to 18 investors).
- Status: Privately Held (backing).
Protego Biopharma's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Protego Biopharma: the Monday email on marks, rounds and moves
Protego Biopharma funding rounds
3 roundsWho backs Protego Biopharma
12+Membership and data by Private Market View
Protego Biopharma valuation
Protego Biopharma's last reported valuation was $217 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
How much has Protego Biopharma raised?
Protego Biopharma has raised $182 million in total; 3 of its rounds are on record, from 2019 on. The largest on record was a $51 million later-stage round in Oct 2021; the most recent was a $32.9 million early-stage round in Oct 2025.
Protego Biopharma has filed 3 Form Ds with the SEC since 2019, most recently in Dec 2025 ($32.9 million sold to 18 investors).
Protego Biopharma investors
12 investors are on record for Protego Biopharma, including Lightspeed Venture Partners, Johnson & Johnson Innovation - JLABS, Digitalis Ventures and Forbion. By type, the record holds 4 venture capital firms and 1 private equity firm. The early-stage round in Oct 2025 drew 18 investors.
About Protego Biopharma
Developer of a small molecule therapeutics platform designed to reprogram protein folding for the treatment of various systemic amyloid diseases and protein misfolding diseases. The company's drug discovery platform in order to address the protein misfolding problem, modulates the energetics of proteins using pharmacological chaperones and/or modulates the cellular folding, secretory and stress pathways, enabling doctors to obtain disease-modifying therapeutics.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2011
- Employees
- 22
- Website
- protegobio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.